ScreenerHero

IPSC Century Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · centurytx.com
1.280USD-3.03%Mkt Cap: 231.78M $P/E: —

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candida…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap231.78M USD
Enterprise Value157.97M USD
Revenue (TTM)0 USD
Gross Profit-78.93M USD
Net Income (TTM)-9.58M USD
Revenue/Share0.00 USD
Last Price1.280 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees78
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.93
PEG—
EV/EBITDA-1.66
EV/Revenue—
P/SInfinity
P/B1.03
EPS (TTM)-0.82
EPS (Forward)-0.45
52W Range
0.435032% of range3.040
52W High3.040 USD
52W Low0.4350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-8.78%
ROE-6.03%
ROA-4.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-103.88M USD
CapEx (TTM)848.00K USD
FCF Margin—
FCF Yield-21.75%
Net Debt-81.05M USD
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity0.27
Current Ratio8.28
Quick Ratio8.04
Book Value/Sh1.29 USD
Cash/Share0.66 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.750 USD
Upside (mean)+271.1%
Target Range2.000 USD – 8.000 USD
2.000+271.1% to mean8.000
# Analysts4
Ownership
Shares Out.181.08M
Float101.25M
Insiders8.14%
Institutions87.43%
Short Interest
Short Ratio73.0d
Short % Float16.33%
Short % Out.16.21%
Shares Short29.35M
Short (prev mo.)29.37M
Technical
SMA 501.946 (-34.2%)
SMA 2002.074 (-38.3%)
Beta1.67
S&P 52W Chg16.45%
Avg Vol (30d)582.28K
Avg Vol (10d)550.43K
Technical Indicators
RSI (14)20.1
MACD-0.1667
MACD Signal-0.1206
MACD Hist.-0.0461
BB Upper2.202 USD
BB Middle1.746 USD
BB Lower1.291 USD
BB Width52.14%
ATR (14)0.1190 USD
Vol Ratio (20d)1.06x